FIELD: pharmaceutical industry.
SUBSTANCE: invention relates to the use of peptide compound containing amino acid sequence FFSFGGAL to suppress activity of cathepsin S, which causes apoptosis induction in a tumor cell. Invention also relates to the use of peptide compound containing amino acid sequence FFSFGGAL for the preparation of a pharmaceutical composition for inhibition of cathepsin S activity, which causes apoptosis induction in a tumor cell.
EFFECT: therapeutic agent for treatment of diseases associated with impaired expression of cathepsin S and/or BCL-2 family proteins.
2 cl, 8 dwg, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PEPTIDE COMPOUNDS FOR INDUCTION OF APOPTOSIS IN TUMOR CELL | 2021 |
|
RU2785794C2 |
| SPECIFIC PEPTIDE INHIBITORS OF CYSTEINE CATHEPSINS | 2020 |
|
RU2752531C1 |
| METHOD FOR DETERMINING AMOUNT OF Bel-2 AND Bax PROTEINS IN VASCULAR WALL IN PATIENTS WITH OBLITERATING ATHEROSCLEROSIS OF ARTERIES OF LOWER EXTREMITIES | 2020 |
|
RU2751822C1 |
| PROAPOPTOSIS PROTEINS-CONTAINING THERAPEUTIC AGENTS | 2002 |
|
RU2319709C2 |
| NEW CHEMICAL COMPOUND THAT STIMULATES PRODUCTION OF HUMAN INTERFERON-BETA BY ACTIVATING STING SIGNALING PATHWAY AND METHOD OF ITS PREPARATION | 2023 |
|
RU2811736C1 |
| METHOD FOR PRODUCING RECOMBINANT FRAGMENT OF HUMAN PLASMINOGEN POSSESSING ANTIANGIOGENIC ACTION | 2011 |
|
RU2458987C1 |
| SMALL MOLECULE INHIBITORS OF THE PHOSPHORYLATED BCL-2-ASSOCIATED DEATH PROMOTER (BAD) | 2018 |
|
RU2799873C2 |
| METHOD TO PRODUCE RECOMBINANT ANTI-ANGIOGENIC POLYPEPTIDE | 2012 |
|
RU2488635C1 |
| MULTI-EPITOPE POLYPEPTIDE FOR IMMUNIZATION AGAINST MYCOBACTERIUM TUBERCULOSIS | 2023 |
|
RU2824195C1 |
| METHOD OF ISOLATION OF HIGH-MOLECULAR PROTEIN ACTIVATION COMPLEX OF HUMAN CASPASE-2 | 2016 |
|
RU2671510C1 |
